[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 6045 Introduced in House (IH)]

<DOC>






118th CONGRESS
  1st Session
                                H. R. 6045

  To direct the Comptroller General of the United States to conduct a 
study and submit a report on the efficacy of Federal drug surveillance 
                    systems, and for other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                            October 25, 2023

  Ms. Caraveo (for herself and Mr. Kean of New Jersey) introduced the 
   following bill; which was referred to the Committee on Energy and 
                                Commerce

_______________________________________________________________________

                                 A BILL


 
  To direct the Comptroller General of the United States to conduct a 
study and submit a report on the efficacy of Federal drug surveillance 
                    systems, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Curbing Illicit Drug Threats Act''.

SEC. 2. GAO STUDY AND REPORT ON EFFICACY OF FEDERAL DRUG SURVEILLANCE 
              SYSTEMS.

    (a) Study.--The Comptroller General of the United States shall 
conduct a study on--
            (1) the efficacy of Federal drug surveillance systems in 
        providing up-to-date information on illicit drug use in the 
        United States, including any limitations affecting such 
        efficacy; and
            (2) how such systems are used to address illicit drug use 
        in the United States.
    (b) Report.--Not later than 18 months after the date of enactment 
of this Act, the Comptroller General of the United States shall 
complete the study under subsection (a) and submit to Congress a report 
containing--
            (1) the findings and conclusions of such study; and
            (2) any recommendations for legislative or administrative 
        actions to improve the efficacy of the Federal drug 
        surveillance systems examined in such study, including any 
        recommendations pertaining to interagency communication or data 
        collection procedures.
    (c) Federal Drug Surveillance Systems Defined.--In this section, 
the term ``Federal drug surveillance systems'' includes--
            (1) the Drug Overdose Surveillance and Epidemiology System 
        of the Centers for Disease Control and Prevention (commonly 
        known as ``DOSE'');
            (2) the State Unintentional Drug Overdose Reporting System 
        of the Centers for Disease Control and Prevention (commonly 
        known as ``SUDORS'');
            (3) the National Drug Early Warning System of the National 
        Institute on Drug Abuse (commonly known as ``NDEWS''); and
            (4) the Drug Abuse Warning Network of the Substance Abuse 
        and Mental Health Services Administration (commonly known as 
        ``DAWN'').
                                 <all>